NASDAQ:NARI Inari Medical (NARI) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free NARI Stock Alerts $47.98 +0.58 (+1.22%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$47.25▼$49.0550-Day Range$40.65▼$59.0352-Week Range$39.90▼$71.85Volume10.14 million shsAverage Volume1.70 million shsMarket Capitalization$2.78 billionP/E RatioN/ADividend YieldN/APrice Target$73.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Inari Medical alerts: Email Address Inari Medical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside53.6% Upside$73.71 Price TargetShort InterestHealthy7.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 12 Articles This WeekInsider TradingSelling Shares$1.65 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.39) to $0.37 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.27 out of 5 starsMedical Sector373rd out of 939 stocksSurgical & Medical Instruments Industry46th out of 97 stocks 3.3 Analyst's Opinion Consensus RatingInari Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $73.71, Inari Medical has a forecasted upside of 53.6% from its current price of $47.98.Amount of Analyst CoverageInari Medical has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.23% of the float of Inari Medical has been sold short.Short Interest Ratio / Days to CoverInari Medical has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inari Medical has recently decreased by 29.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInari Medical does not currently pay a dividend.Dividend GrowthInari Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NARI. Previous Next 2.9 News and Social Media Coverage News SentimentInari Medical has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Inari Medical this week, compared to 4 articles on an average week.Search Interest12 people have searched for NARI on MarketBeat in the last 30 days. MarketBeat Follows7 people have added Inari Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inari Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,645,200.00 in company stock.Percentage Held by Insiders10.60% of the stock of Inari Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Inari Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inari Medical are expected to grow in the coming year, from ($0.39) to $0.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inari Medical is -1,599.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inari Medical is -1,599.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInari Medical has a P/B Ratio of 5.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Inari Medical Stock (NASDAQ:NARI)Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Read More NARI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NARI Stock News HeadlinesMarch 21, 2024 | insidertrades.comInsider Selling: Inari Medical, Inc. (NASDAQ:NARI) Director Sells 40,000 Shares of StockMarch 26, 2024 | americanbankingnews.comInari Medical (NASDAQ:NARI) Stock Price Down 4.3% Following Analyst DowngradeMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 25, 2024 | marketwatch.comInari Medical Shares Gain After Index MoveMarch 23, 2024 | morningstar.comInari Medical, Inc. (NARI) Plummets on News of DOJ Investigation – Hagens BermanMarch 23, 2024 | americanbankingnews.comInari Medical (NASDAQ:NARI) Given New $52.00 Price Target at Truist FinancialMarch 22, 2024 | markets.businessinsider.comForecasting The Future: 7 Analyst Projections For Inari MedicalMarch 22, 2024 | americanbankingnews.comWilliam Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) StockMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 20, 2024 | finance.yahoo.comDirector William Hoffman Sells 40,000 Shares of Inari Medical Inc (NARI)March 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Inari Medical, Inc. (NARI) and Encourages Investors with Losses to Contact the FirmMarch 19, 2024 | finance.yahoo.comNARI Apr 2024 65.000 callMarch 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inari Medical, Inc.- NARIMarch 16, 2024 | investing.comInari Medical CFO sells shares worth over $250kMarch 16, 2024 | finanznachrichten.deInari Medical, Inc.: Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT RegistryMarch 12, 2024 | globenewswire.comInari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT RegistryMarch 12, 2024 | prnewswire.comNARI INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inari Medical, Inc. Investors to Inquire About Securities Class Action Investigation - NARIMarch 12, 2024 | prnewswire.comInari Medical Investigation: Kessler Topaz Meltzer & Check, LLP Investigates The Inari Medical, Inc. (NASDAQ: NARI) for Potential Securities ViolationsMarch 11, 2024 | businesswire.comInari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 11, 2024 | businesswire.comInari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 7, 2024 | markets.businessinsider.comInari Medical, Inc. (NARI) Plummets on News of DOJ Investigation - Hagens BermanMarch 6, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of InvestorsMarch 6, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inari Medical, Inc.- NARIMarch 6, 2024 | tmcnet.comInari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 6, 2024 | markets.businessinsider.comInari Medical Buy Rating Justified by Industry-Standard Physician Payments and Resilient Sector TrendsMarch 6, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of InvestorsMarch 6, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of InvestorsSee More Headlines Receive NARI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NARI CUSIPN/A CIK1531048 Webwww.inarimedical.com Phone877-923-4747FaxN/AEmployees1,300Year FoundedN/APrice Target and Rating Average Stock Price Target$73.71 High Stock Price Target$100.00 Low Stock Price Target$52.00 Potential Upside/Downside+53.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,640,000.00 Net Margins-0.33% Pretax Margin0.86% Return on Equity1.23% Return on Assets0.97% Debt Debt-to-Equity RatioN/A Current Ratio3.09 Quick Ratio2.52 Sales & Book Value Annual Sales$493.63 million Price / Sales5.63 Cash Flow$0.09 per share Price / Cash Flow522.94 Book Value$8.07 per share Price / Book5.95Miscellaneous Outstanding Shares57,960,000Free Float51,817,000Market Cap$2.78 billion OptionableOptionable Beta0.84 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Andrew J. Hykes (Age 50)CEO, President & Director Comp: $863.78kMr. Mitchell C. Hill (Age 65)Chief Financial Officer Comp: $811.08kDr. Thomas M. Tu M.D. (Age 51)Chief Medical Officer Comp: $812.94kMr. Paul A. Koehn (Age 61)Senior Vice President of Operations Mr. Kevin StrangeSenior Vice President of Finance, Accounting, Strategy & Business DevelopmentMr. John Hsu C.F.A.Vice President of Investor RelationsMs. Angela AhmadGeneral Counsel & SecretaryMr. Eric KhairySenior Vice President of MarketingMr. John R. Borrell (Age 57)Senior Vice President of Sales Ms. Tara DunnSenior VP & GM of LimFlowMore ExecutivesKey CompetitorsIntegra LifeSciencesNASDAQ:IARTICU MedicalNASDAQ:ICUIPROCEPT BioRoboticsNASDAQ:PRCTTandem Diabetes CareNASDAQ:TNDMNuVasiveNASDAQ:NUVAView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 573 shares on 3/22/2024Ownership: 0.002%William HoffmanSold 40,000 sharesTotal: $1.65 M ($41.13/share)Vanguard Group Inc.Bought 325,586 shares on 3/11/2024Ownership: 8.693%Wellington Management Group LLPSold 532,811 shares on 3/5/2024Ownership: 7.873%Goldman Sachs Group Inc.Sold 6,296 shares on 3/1/2024Ownership: 0.315%View All Insider TransactionsView All Institutional Transactions NARI Stock Analysis - Frequently Asked Questions Should I buy or sell Inari Medical stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NARI shares. View NARI analyst ratings or view top-rated stocks. What is Inari Medical's stock price target for 2024? 6 equities research analysts have issued 12 month target prices for Inari Medical's stock. Their NARI share price targets range from $52.00 to $100.00. On average, they predict the company's stock price to reach $73.71 in the next year. This suggests a possible upside of 53.6% from the stock's current price. View analysts price targets for NARI or view top-rated stocks among Wall Street analysts. How have NARI shares performed in 2024? Inari Medical's stock was trading at $64.92 at the beginning of 2024. Since then, NARI stock has decreased by 26.1% and is now trading at $47.98. View the best growth stocks for 2024 here. Are investors shorting Inari Medical? Inari Medical saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 3,580,000 shares, a drop of 29.1% from the February 29th total of 5,050,000 shares. Based on an average daily volume of 946,700 shares, the days-to-cover ratio is presently 3.8 days. Currently, 7.2% of the company's stock are sold short. View Inari Medical's Short Interest. When is Inari Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our NARI earnings forecast. How were Inari Medical's earnings last quarter? Inari Medical, Inc. (NASDAQ:NARI) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.09. The company had revenue of $132.10 million for the quarter, compared to analyst estimates of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive trailing twelve-month return on equity of 1.23%. The business's quarterly revenue was up 22.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) EPS. What ETFs hold Inari Medical's stock? ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Principal Healthcare Innovators ETF (BTEC) and IQ Healthy Hearts ETF (HART).iShares U.S. Medical Devices ETF (IHI). What guidance has Inari Medical issued on next quarter's earnings? Inari Medical issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $588.3 million. What other stocks do shareholders of Inari Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY). When did Inari Medical IPO? Inari Medical (NARI) raised $110 million in an initial public offering (IPO) on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers. Who are Inari Medical's major shareholders? Inari Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.75%), Vanguard Group Inc. (8.69%), Wellington Management Group LLP (7.87%), Franklin Resources Inc. (4.91%), Brown Advisory Inc. (2.96%) and Voya Investment Management LLC (1.34%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman. View institutional ownership trends. How do I buy shares of Inari Medical? Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NARI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inari Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.